Moleculin to Present at 38th Annual ROTH Conference

Core Viewpoint - Moleculin Biotech, Inc. is actively participating in the 38th Annual ROTH Conference, showcasing its advancements in therapeutic candidates for hard-to-treat tumors and viruses [1]. Company Overview - Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapies for difficult-to-treat tumors and viruses. Its lead program, Annamycin, is designed to avoid multidrug resistance and cardiotoxicity associated with current anthracyclines [2]. Clinical Trials - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML). The trial follows a successful Phase 1B/2 study and aims to de-risk the development pathway towards potential approval [3]. Additional Developments - Moleculin is also developing WP1066, an Immune/Transcription Modulator targeting various cancers, and has a portfolio of antimetabolites, including WP1122 for treating pathogenic viruses and certain cancer indications [4].